XOMA Corporation releases research update from XOMA 358's clinical studies
The study involves patients who have severe hypoglycemia because of congenital hyperinsulinism (CHI) as well as post-bariatric surgery (PBS). These two rare health conditions are due to abnormal insulin function.
This latest update is a summary of the company’s clinical progress with XOMA 358. XOMA previously gave a report in a conference call and a webcast.
“The initial data from the XOMA 358 phase-two clinical studies confirms that our first-in-class allosteric antibody is exhibiting an inhibition on insulin signaling, the desired mechanism-of-action,” John Varian, CEO of XOMA, said. “This means that for patients who are not able to properly regulate their high insulin levels and experience severe bouts of hypoglycemia, such as those diagnosed with congenital hyperinsulinism and certain post-bariatric surgery patients, XOMA 358 could provide benefit in preventing hypoglycemic episodes. When we consider the totality of preclinical and clinical evidence, which demonstrates that XOMA 358 down-regulates insulin signaling by binding to the insulin receptor in an allosteric manner, we believe XOMA 358 is ready for advancement into phase 2b multi-dose studies.”
Organizations in this story
XOMA Corporation 2910 Seventh Street Berkeley, CA 94710-2700